Smith & Nephew Warning Letter Details Uncleared Product Modifications
This article was originally published in The Gray Sheet
Executive Summary
A warning letter posted by FDA July 8 provides more details behind Smith & Nephew’s recent announcement that it was temporarily halting sales of its Renasys line of negative pressure wound therapy devices.
You may also be interested in...
Smith & Nephew Halts Sales Of Renasys Negative Pressure Wound Therapy
FDA instructed to the company to obtain new clearances for design modifications already made to Renasys. The company says 510(k)s for these changes are pending.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.